TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A modeling study presented at the American Heart Association’s 2026 Hypertension Scientific Sessions estimates that expanding blood pressure treatment across 20 upper- and lower-middle-income countries could prevent 518,476 cardiovascular deaths each year. The figure is a modeled estimate, not a count of deaths already prevented or a forecast for every country; the study did not include low-income countries.
A preliminary modeling study presented at the American Heart Association’s Hypertension Scientific Sessions estimates that raising blood pressure control to levels achieved in high-performing U.S. health systems could prevent 518,476 cardiovascular deaths each year across 20 upper- and lower-middle-income countries. The estimate describes potential impact under the study’s modeled scenario, not deaths already avoided or a confirmed outcome of a treatment program.
The researchers compared current access to several preventive services with a scenario in which each reached approximately 80% of eligible patients, a level based on high-performing U.S. health systems. In that model, improved hypertension control had the largest estimated effect on cardiovascular deaths. The analysis also estimated that wider statin treatment, when indicated for high cholesterol, could prevent 340,682 cardiovascular deaths annually, while improved blood sugar control among people with Type 1 or Type 2 diabetes could prevent 309,520.
Current service gaps were substantial in the countries studied. The model estimated that about one in five adults with hypertension had blood pressure below 140/90 mm Hg. It also found that 16% of people with high cholesterol used statins, 39% of people with diabetes had blood sugar below the study’s optimal threshold, and 14% to 26% of eligible people received routinely indicated cancer screening. The blood pressure measure in this finding is not the same as the treatment goal in the American Heart Association’s 2025 adult guideline, which recommends a target below 130/80 mm Hg.
The analysis considered six services: blood pressure control, statin treatment when indicated, glucose control for people with diabetes, and screening for colon, breast and cervical cancers. Increased colon cancer screening was estimated to prevent 206,767 colon cancer-related deaths a year in the modeled scenario. The researchers also reported blood-pressure-related estimates of 223,282 annual deaths in upper-middle-income countries and 223,655 in lower-middle-income countries.
Blood Pressure Is the Largest Modeled Opportunity
The findings point to a large potential role for routine hypertension care in reducing cardiovascular deaths, particularly where diagnosis, access to treatment or ongoing control remain limited. The scale of the estimate reflects both the number of people who could receive care and the model’s assumption that services could reach approximately 80% of eligible patients. It should not be read as a prediction that a single intervention would immediately save that number of lives.
High blood pressure is a major modifiable cardiovascular risk factor. When it is not controlled, it can damage blood vessels and contribute to conditions including heart disease and stroke. The study’s broader comparison also matters: it suggests blood pressure services may offer a larger modeled reduction in deaths than the other preventive services assessed, while showing that statin use and diabetes care could also have substantial potential effects.
The burden is especially relevant in countries with fewer resources for prevention. The source report says noncommunicable diseases account for roughly three out of five deaths worldwide, and about 73% of those deaths occur in low- and middle-income countries. However, the study included only middle-income countries, so its results do not directly quantify potential effects in low-income settings.
Products Worth Considering
OMRON Complete 2-in-1 Upper Arm Blood Pressure Monitor with EKG
Withings BPM Vision Blood Pressure Monitor with Wi-Fi and Bluetooth
Levoit Eleva 500X HEPA Air Purifier for Large Rooms
As an affiliate, we earn on qualifying purchases.
How the 20-Country Model Was Built
Researchers analyzed existing data for 20 countries selected for having high numbers of deaths from noncommunicable diseases. They used eligibility criteria and treatment or screening targets based on major clinical guidelines, then modeled the effect of increasing use of six evidence-based preventive services. Results were grouped by World Bank income categories. The comparison level—approximately 80% of eligible patients—was drawn from high-performing U.S. health systems, rather than from a trial conducted in the countries being assessed.
The meeting presentation took place at the American Heart Association’s Hypertension Scientific Sessions 2026, held in Arlington, Virginia, from October 7 to 11. The work was described as preliminary research. Scott Pilla, an associate professor of medicine at the Johns Hopkins University School of Medicine and a study author, said the team examined whether expanded preventive care could reduce cardiovascular deaths across the selected countries.
Daniel W. Jones, who chaired the writing committee for the AHA’s 2025 adult hypertension guideline and was not involved in the study, said earlier research supports following evidence-based recommendations to lower risks associated with high blood pressure. He said appropriate treatment includes lifestyle measures and medication when indicated. The guideline recommends a blood pressure treatment goal of less than 130/80 mm Hg for adults with hypertension; the model’s reported current-control estimate used a threshold below 140/90 mm Hg.
“We analyzed existing data to assess if expanding use of NCD preventive healthcare services across 20 countries worldwide could reduce cardiovascular death.”
— Scott Pilla, M.D., M.H.S., associate professor of medicine at Johns Hopkins University School of Medicine and a study author
Limits of the Mortality Estimates
The 518,476 figure is a modeled annual estimate. It depends on assumptions about eligible populations, current service use, treatment targets and the ability to raise coverage to approximately 80%. The source material does not establish that reaching that coverage level is feasible within a particular timeframe, or that the modeled reduction would be achieved in practice.
The study covered 20 upper- and lower-middle-income countries; no low-income countries were included. The supplied report does not name the countries or provide enough methodological detail to assess country-by-country estimates, uncertainty ranges or how the researchers addressed differences in health systems and data quality. It also does not state that the findings have been published in a peer-reviewed journal. Those details limit how broadly the results can be applied.
The reported estimate uses a blood pressure control threshold below 140/90 mm Hg to describe current control, while the AHA’s 2025 guideline target for adults with hypertension is below 130/80 mm Hg. The source material does not explain how that difference affects the modeled deaths prevented. The results should therefore be understood as a comparison generated by the study’s stated methods, not as a direct estimate of the effect of adopting the AHA target worldwide.
Further Study and Implementation Questions
The research was presented at a scientific meeting as preliminary work. The supplied information does not identify a planned publication date, an implementation program or a follow-up study. Further reporting should establish the full list of countries, detailed modeling assumptions, uncertainty ranges and whether the findings undergo peer review.
For health systems, the practical next steps suggested by the analysis are improving access to blood pressure measurement, diagnosis, follow-up and evidence-based treatment. Whether countries can reach the model’s 80% coverage assumption will depend on local resources and health-system capacity; the study does not specify a single delivery plan. The researchers also assessed statin use, diabetes glucose control and cancer screening, so decisions about prevention priorities will require attention to local disease burdens and service gaps.
Key Questions
What does the 518,476 figure mean?
It is the study’s estimate of annual cardiovascular deaths that could be prevented if blood pressure control reached the modeled level across 20 upper- and lower-middle-income countries. It is not a count of deaths already prevented.
How did researchers estimate the potential reduction?
They analyzed existing data and modeled expanded use of preventive services, comparing current levels with coverage of approximately 80% of eligible patients, based on high-performing U.S. health systems.
Did the study include low-income countries?
No. The source report says the 20 countries were in the upper-middle-income and lower-middle-income categories. It did not include lower-income countries, so the estimate does not directly cover them.
What blood pressure target does the AHA guideline recommend?
The American Heart Association’s 2025 adult hypertension guideline recommends a treatment goal of less than 130/80 mm Hg for adults with hypertension. The study’s estimate that about one in five adults had controlled blood pressure used a below-140/90 mm Hg threshold.
Were other preventive services included in the analysis?
Yes. The model also assessed statin treatment when indicated, glucose control for people with diabetes, and screening for colon, breast and cervical cancers. The source report described the blood pressure estimate as the largest modeled reduction in cardiovascular deaths among the services assessed.
Source: rss
